Expiration date: 02/2025
Structure and Composition:
Tablets complete 1 set.
pink tablet contains:
0.05 mg levonorgestrel
0.03 mg ethinylestradiol
white tablet contains:
0.075 mg of levonorgestrel
0.04 mg ethinylestradiol
dark yellow tablet contains:
0.125 mg levonorgestrel
0.03 mg ethinylestradiol
Excipients:
tablet core: silica colloidal anhydrous magnesium stearate, talc, corn starch, lactose monohydrate
sheath: talc, calcium carbonate, sucrose, titanium dioxide, macrogol 6000 copovidone colloidal silicon anhydrous sodium carboxymethylcellulose, povidone red iron oxide, yellow iron oxide
in 6 pack strip cellular pink tablets, 5 - 10 and a white color - dark yellow total 21 pieces. 1 in the box 3 or packaging.
Pharmachologic effect:
It stops ovulation, restores normal hormonal profile of the menstrual cycle, helps the secretory transformation of the endometrium.
Pharmacokinetics:
When administered active substances is rapidly and completely absorbed from the gastrointestinal tract. Cmax in plasma achieved in 2 hours (levonorgestrel) and 1.5 hours (ethinyl estradiol). Active components are metabolized in the liver. T1 / 2 is 2-7 hours Levonorgestrel: 60% excreted by the kidneys, 40% - the intestines ethinylestradiol:. 40% - by the kidneys, 60% - the intestines.
Indications:
Contraception, dysmenorrhea, premenstrual syndrome marked.
Contraindications:
Hypersensitivity, liver disease and gall bladder, severe diabetes, and others. Endocrine system diseases, disorders of lipid metabolism, severe organic heart disease, hypertension, cerebrovascular disease, an increased tendency to thrombosis, sickle-cell anemia, chronic hemolytic anemia, malignant tumors, tetany, syndrome Dubin - Johnson syndrome, Rotor syndrome, pruritus during pregnancy in history, pregnancy, breast-feeding.
Application of pregnancy and breastfeeding:
Contraindicated. At the time of treatment should stop breastfeeding.
Side effect:
Neuralgia, mastalgia, increase or decrease in body weight, reduced glucose tolerance, change in libido, vaginal spotting, headaches, mood lability, fatigue, cramps in the calf muscles, skin rashes.
Drug Interactions:
Effect reduce inducers of microsomal oxidation (rifampicin, barbiturates, phenytoin), broad-spectrum antibiotics (tetracyclines), sulfonamides, pyrazolone derivatives.
Dosage and administration:
Inside, at the same time of the day, as far as possible in the evening, with liquid squeezed small amount of liquid.
For the purpose of contraception three-regolith prescribed daily 1 tablet. a day for 21 days, starting on day 1 of the menstrual cycle, then make a 7-day break, during which bleeding occurs menstrualnopodobnoe. Acceptance of the next pack should be started on the 8th day after the 7-day break.
The drug is carried out as long as there is a need for contraception.
When switching from another oral contraceptive to receive three-Regola applied a similar scheme.
After an abortion, the drug is recommended to start on the same or next day after surgery.
After delivery, the drug is recommended only for women not breastfeeding.
Admission should be started no earlier than the first day of menstruation cycle.
If a woman did not accept three-regolith in due time, should take the missed pill during the next 12 hours. If after taking the pill took 36 hours, contraception can not be considered reliable. However, in order to avoid inter-menstrual bleeding should continue taking the drug have already started packing of net missed (s) tablet (s). At this time, it is recommended to additionally use other non-hormonal method of contraception (most often - a barrier).
For therapeutic purposes: the dosing regimen is determined individually.
Precautionary measures:
Caution should be observed in patients older than 40 years. When using the drug it is recommended to conduct an annual gynecological cytology control. Smoking can increase the frequency and severity of side effects. When planning pregnancy should be discontinued 3 months before its intended use and the occurrence of non-hormonal method of contraception.
